Research Articles - Macular Degeneration
StemCells, Inc. , which launched a Phase I/II clinical trial for its dry age-related macular degeneration (AMD) therapy in October 2012, has begun administering the highest dose of its treatment to patients in the study. The fifth patient in the trial has received a transplant of one million of the company’s human neural stem cells known as HuCNS-SC ® .
Researchers from the University of Wisconsin School of Medicine and Public Health have determined that people taking commonly prescribed blood-pressure medications — including drugs that open and relax blood vessels and regulate heart rhythm — appear to be at increased risk for age-related macular degeneration (AMD). The findings are based on an analysis of data from a long-term study of approximately 5,000 residents of Beaver Dam, Wisconsin, funded by the National Eye Institute.
- The clinical path for an innovative gene therapy designed to restore vision in people with a wide range of advanced retinal diseases is clearer thanks to a productive discussion with the U.S. Food and Drug Administration (FDA) about development plans. RetroSense Therapeutics, the company developing the gene therapy, and the Foundation Fighting Blindness, a funding partner, met with the FDA earlier this week to get feedback on plans to submit an Investigational New Drug (IND) application for launching a clinical trial of the treatment. Known as a pre-IND meeting, the discussion covered
A key to survival for any organism, plant or animal, is energy. And, in humans, every cell gets its energy from a tiny, organ-like structure called a mitochondrion. It operates like a power plant, providing the energy needed to stay alive and functioning. Among their many functions, mitochondria combine sugar and oxygen, which serve as the cells’ supply of fuel.
One consequence of most retinal degenerations, including retinitis pigmentosa and macular degeneration, is that mitochondria operate at reduced capacity,
The IMT provides improved central and detailed vision by focusing and magnifying images onto the functional, outer regions of the recipient’s retina. People with advanced AMD normally experience degeneration of the macula or central region of the retina.
In clinical studies, the device has helped people improve their ability to read, recognize faces, and perform other detailed-oriented tasks. In a 219-participant study, 75 percent of recipients had their level of vision improved from severe impairment to moderate impairment.
Owings Mills, MD — An innovative technology, employing a tiny capsule implanted in the eye, is stabilizing vision in people suffering from dry age-related macular degeneration (AMD). Encapsulated Cell Technology (ECT), developed by Rhode Island-based Neurotech, preserved vision in a majority of the 51 people who participated in a Phase II clinical trial.
There are currently no treatments for dry AMD, which is a leading cause of blindness for people 55 and older in developed countries.
- An emerging low-radiation treatment for wet age-related macular degeneration (AMD) known as Oraya Therapy™ reduced the number of Lucentis™ injections that people receive for the treatment of recurring wet AMD. In Oraya’s 230-person, Phase II/III clinical trial across Europe, the treatment reduced the need for Lucentis injections by 32 percent.
- A 21,000-participant study suggests that moderate alcohol consumption — more than one drink per day — increases the risk of early age-related macular degeneration (AMD) by 20 percent and advanced AMD by 44 percent. The report in the American Journal of Epidemiology was authored by investigators from the Centre for Eye Research Australia.
The research team says that, until its study, there was little evidence